Kazia Doses First Patient in Pediatric AT/RT Study
Sydney, Australia, September 10, 2026 Kazia Therapeutics Limited has announced that the first patient has been dosed in the...
hypochondroplasia
Advertisement
BioMarin Reports Positive Phase 3 VOXZOGO Data
San Rafael, California, September 9, 2026 BioMarin Pharmaceutical Inc. has announced the publication of positive Phase 3 CANOPY-HCH-3 results...
BioMarin Reports Positive VOXZOGO and BMN 333 Data at ENDO 2026
SAN RAFAEL, Calif., June 16, 2026 BioMarin Pharmaceutical Inc. announced new clinical findings from its approved therapy VOXZOGO® (vosoritide)...
BioMarin Reports Positive Phase 3 VOXZOGO Data in Hypochondroplasia
SAN RAFAEL, Calif., May 20, 2026 BioMarin Pharmaceutical Inc. announced positive topline results from the pivotal Phase 3 CANOPY-HCH-3...
Advertisement
